He is suggesting that the Big Oil valuations(carbon bubble) are primarily based on their $7 trillion asset base which will not be available to them to sell as mankind will not be able to utilize these assets as they would cause excessive global warming.
That's my read on his theory.
Anyone doubting the future use and acceptance of Herceptin SC vs IV infusion should read the media release Sept 30/13 on Roche's websight/media/archive involving 400 patients in 12 European countries that had a 92% preference for the SC mode of treatment. Report also addresses significant savings in hospital resources utilized with SC.
New Herceptin jab for breast cancer patients 'cuts treatment time'
By Peter Russell
WebMD UK Health News
Medically Reviewed by Dr Rob Hicks
25th September 2013 - A faster, more comfortable method for giving trastuzumab (Herceptin) to breast cancer patients has been approved by NHS England.
Until now trastuzumab has been delivered into a vein which means patients receive the drug by intravenous drip and each treatment takes between two and three hours. A new subcutaneous formulation of the medication is given by an injection under the skin, which takes just 2 to 5 minutes to administer. Patients will still need to stay in hospital for around an hour and a half after the injection to be monitored, but it will half the time a patient spends in hospital making it a much more convenient treatment.
Reducing risk of recurrence
Trastuzumab is an established treatment for women with HER2 positive breast cancer. In patients with early breast cancer it has been shown to significantly reduce the risk of recurrence of the disease; and in advanced breast cancer it significantly prolongs life.
The NHS estimates that around 20% of women with breast cancer have tumours that will respond to trastuzumab.
NHS England says the new subcutaneous form of trastuzumab will primarily be used to treat women with early breast cancer who currently get the drug with chemotherapy before or after surgery.
Peter Clark, an oncologist who chairs NHS England’s Chemotherapy Clinical Reference Group, says in a statement: "The new subcutaneous formulation of trastuzumab will mean that women who are being treated for early breast cancer can have a much less invasive treatment than the current intravenous treatment.
"This will be of benefit to patients as less time is spent receiving treatment and it is a more comfortable form of receiving this drug."
Cutting NHS costs
NHS England says an extra benefit is that the new formulation of trastuzumab should save the NHS money because the medication is given as a fixed dose irrespective of the patient's size or weight. That means less wastage and cuts the overall cost of the drug.
Also, less preparation and administration will free up specialist cancer nurses and hospital pharmacists who will have more time to spend with patients requiring chemotherapy treatment.
Approval for subcutaneous injection of trastuzumab applies only to England.
Jackie Harris, clinical nurse specialist at Breast Cancer Care, says in a statement: "This is a more time and cost efficient delivery of Herceptin through subcutaneous (SC) injection, which could greatly improve the quality of life of patients with HER2-positive breast cancer.
"The speed of the SC injection would cut down the time patients have to spend in clinics and would be far more convenient, allowing patients to live their lives with less disruption from treatment.
"This approval is a welcome step and we hope that this treatment administration will be made available across the UK as soon as possible."